Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Thyroid Neoplasms 2Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Paraganglioma 1Paget Disease, Extramammary 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Giant Cell Tumor of Bone 1Gestational Trophoblastic Disease 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Fibroma 1

Interventions

Magnetic Resonance Spectroscopy 10Paclitaxel 7Iodine-131 6Fluorodeoxyglucose F18 6Sorafenib 5vandetanib 4trametinib 4selpercatinib 4dabrafenib 4pembrolizumab 3fosbretabulin 3cabozantinib 3Vemurafenib 3Sunitinib 3Specimen Handling 3Nivolumab 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2romidepsin 2pazopanib 2lenvatinib 2combretastatin 2Trastuzumab 2Thyrotropin Alfa 2Ipilimumab 2Gefitinib 2FAPI-46 2Everolimus 2Doxorubicin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Neoplasms × CTLA-4 Antigen × Endocrine × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03914300 2026-06-01

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled 11 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡